Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Antisoma's Theragyn granted orphan drug status in the U.S.

April 6, 1999

DSMB completes interim evaluation of Maxamine phase III clinical trials

April 1, 1999

Reanalysis of data attributes greater efficacy to Multikine

March 30, 1999

Procyon receives Canadian patent for PSP94

March 30, 1999

AltaRex updates OvaRex MAb and BrevaRex MAb clinical progress

March 29, 1999

Maxim allowed additional U.S. patent for Maxamine technology

March 22, 1999

Mouse study provides preliminary indications of the antitumor efficacy of AR-209

March 18, 1999

Clinical trials of needle-free delivery of DNA vaccine begin

March 18, 1999

Second prostate cancer study initiated with Multikine

March 16, 1999

Genzyme Molecular Oncology initiates clinical trials of combined-antigen melanoma vaccine

March 10, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...